Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

• Status: Completed
• Trial end date: 2020-08-19

Summary

The purpose of this study is to test the safety of the drug olaparib at different dose levels. It will be given with the standard initial chemotherapy for cancer as well as a drug called bevacizumab.

• Phase: Phase 1

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborators: AstraZeneca; Genentech, Inc.
• Treatments: Albumin-Bound Paclitaxel; Bevacizumab; Cisplatin; Olaparib; Paclitaxel